TOTUOP
RAPT

Trustees of The University of Pennsylvania’s RAPT Therapeutics RAPT Stock Holding History

Trustees of The University of Pennsylvania’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,254
Closed -$183K – 6
2022
Q2 		$183K Buy
+1,254
New +$167K 0.22% 5

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Trustees of The University of Pennsylvania's RAPT Position: Q3 2022 in Review

Trustees of The University of Pennsylvania sold out of RAPT Therapeutics (RAPT) in Q3 2022, closing a stake of 1,254 shares — an estimated $183K sold.

Trustees of The University of Pennsylvania first reported a position in RAPT in Q2 2022 and held it in 1 quarter. The position peaked at $183K in Q2 2022. 98 funds tracked by Wall St. Rank hold RAPT as of Q3 2022.

  • Trustees of The University of Pennsylvania reported no remaining RAPT Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Trustees of The University of Pennsylvania sold 1,254 RAPT Therapeutics shares in Q3 2022, an estimated $183K.
  • Trustees of The University of Pennsylvania first reported a position in RAPT Therapeutics in Q2 2022 and held it in 1 quarter.
  • Trustees of The University of Pennsylvania's RAPT Therapeutics position peaked at $183K in Q2 2022.
  • 98 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q3 2022.

Based on Trustees of The University of Pennsylvania's 13F filing for Q3 2022, filed 10 Nov 2022.